Profile data is unavailable for this security.
About the company
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 179 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.
- Revenue in GBP (TTM)35.94bn
- Net income in GBP2.66bn
- Incorporated1992
- Employees83.50k
- LocationAstraZeneca PLC1 Francis Crick AvenueCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 207 304 5000
- Fax+44 207 604 8151
- Websitehttps://www.astrazeneca.com/
Mergers & acquisitions
| Acquired company | AZN:LSE since announced | Transaction value |
|---|---|---|
| Neogene Therapeutics | 0.96% | -- |
| Neogene Therapeutics Inc | 1.05% | 320.00m |
| TeneoTwo Inc | 3.31% | 1.27bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonza Group AG | 5.48bn | 1.07bn | 35.01bn | 17.49k | 32.65 | 3.74 | 21.92 | 6.39 | 16.34 | 16.34 | 83.69 | 142.66 | 0.3681 | 2.28 | 5.95 | 355,722.00 | 7.20 | 5.30 | 8.63 | 6.48 | 39.18 | 39.90 | 19.57 | 15.20 | 1.27 | 21.61 | 0.1731 | 28.41 | 15.05 | 6.47 | 80.27 | 12.84 | 32.93 | 4.94 |
| Bayer AG | 44.58bn | 3.65bn | 49.09bn | 101.37k | 13.46 | 1.44 | 5.24 | 1.10 | 4.22 | 4.22 | 51.65 | 39.47 | 0.414 | 1.59 | 4.98 | 500,537.60 | 3.40 | -1.11 | 4.62 | -1.45 | 60.84 | 58.98 | 8.21 | -3.04 | 0.6876 | 5.01 | 0.5169 | -- | 15.10 | 7.70 | 315.00 | 5.02 | 4.50 | -2.72 |
| GSK plc | 29.32bn | 4.26bn | 58.19bn | 69.40k | 12.10 | 5.41 | 8.06 | 1.98 | 1.17 | 3.83 | 8.03 | 2.63 | 0.4212 | 1.72 | 3.93 | 422,536.00 | 7.07 | 6.39 | 11.31 | 10.42 | 67.98 | 69.55 | 16.78 | 15.90 | 0.6849 | 9.22 | 0.6752 | 93.37 | 18.74 | -0.5778 | 51.73 | 10.27 | 0.5035 | -9.34 |
| Sanofi SA | 39.88bn | 7.35bn | 110.78bn | 91.57k | 15.02 | 1.68 | 12.04 | 2.78 | 6.66 | 6.66 | 36.19 | 59.70 | 0.3676 | 1.55 | 5.68 | 495,659.20 | 6.82 | 5.80 | 8.37 | 7.02 | 69.83 | 68.49 | 18.54 | 17.00 | 1.05 | 69.89 | 0.2225 | 59.84 | 15.86 | 4.62 | 34.52 | 17.28 | 2.39 | 3.28 |
| Novartis AG | 41.92bn | 5.63bn | 168.20bn | 101.70k | 28.84 | 3.26 | 16.74 | 4.01 | 2.91 | 2.91 | 21.66 | 25.74 | 0.4152 | 2.17 | 6.44 | 467,801.00 | 5.58 | 9.09 | 7.32 | 11.77 | 71.01 | 70.98 | 13.44 | 23.68 | 1.04 | 11.76 | 0.3196 | 59.94 | -2.15 | 3.60 | -71.05 | -1.49 | 3.09 | 3.79 |
| AstraZeneca plc | 35.94bn | 2.66bn | 171.77bn | 83.50k | 64.89 | 5.72 | 24.80 | 4.78 | 1.71 | 1.71 | 23.04 | 19.37 | 0.4394 | 1.29 | 4.40 | 430,418.10 | 3.26 | 2.63 | 4.31 | 3.62 | 80.13 | 78.99 | 7.42 | 6.35 | 0.6806 | 6.81 | 0.441 | 187.07 | 18.53 | 14.57 | 2,835.71 | 6.63 | 9.68 | 1.13 |
| Roche Holding AG | 55.76bn | 10.94bn | 184.26bn | 103.61k | 16.73 | 7.34 | 12.04 | 3.30 | 15.36 | 15.36 | 78.32 | 35.03 | 0.7013 | 2.27 | 5.65 | 610,743.80 | 15.00 | 16.21 | 25.31 | 25.33 | 70.75 | 71.07 | 21.38 | 22.62 | 0.9256 | 19.25 | 0.4419 | 59.33 | 0.7643 | 3.49 | -10.83 | 7.26 | 2.63 | 2.74 |
| Novo Nordisk A/S | 20.87bn | 6.55bn | 218.77bn | 54.39k | 43.76 | 28.68 | 29.88 | 10.48 | 24.32 | 24.32 | 77.51 | 37.11 | 0.8122 | 1.29 | 3.88 | 3,253,250.00 | 25.48 | 29.83 | 51.58 | 58.58 | 83.92 | 83.76 | 31.38 | 32.86 | 0.693 | 13.02 | 0.236 | 45.88 | 25.68 | 9.64 | 16.27 | 7.81 | 11.27 | 9.57 |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2022 | 75.47m | 4.87% |
| Wellington Management Co. LLPas of 31 Jan 2022 | 64.15m | 4.14% |
| The Vanguard Group, Inc.as of 01 Mar 2023 | 53.48m | 3.45% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2022 | 35.78m | 2.31% |
| BlackRock Fund Advisorsas of 01 Mar 2023 | 29.07m | 1.88% |
| BlackRock Advisors (UK) Ltd.as of 01 Mar 2023 | 21.53m | 1.39% |
| GQG Partners LLCas of 01 Mar 2023 | 17.83m | 1.15% |
| BlackRock Advisors LLCas of 01 Mar 2023 | 15.47m | 1.00% |
| SSgA Funds Management, Inc.as of 01 Mar 2023 | 15.45m | 1.00% |
| Schroder Investment Management Ltd.as of 01 Mar 2023 | 14.60m | 0.94% |
